Mini review

Severe acute respiratory syndrome coronavirus 2 variants—Possibility of universal vaccine design: A review

Eunhye Yoon a,1, Dahyun Kim a,1, Hyeun Jeon a, Yejin Kwon a, Yejin Jang a, Sulhee Kim a,b,⇑, Kwang Yeon Hwang a,b,⇑

a Division of Biotechnology, College of Life Sciences and Biotechnology, Seoul 02841, South Korea
b Institute of Bioresource, Korea University, Seoul 02841, South Korea

A R T I C L E   I N F O

Article info
Article history:
Received 28 March 2022
Accepted 18 June 2022
Available online 23 June 2022

Keywords:
COVID-19
Coronavirus
Antigen
Oral drug
Universal vaccine
Receptor-binding domain

A B S T R A C T

Both novel and conventional vaccination strategies have been implemented worldwide since the onset of coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite various medical advances in the treatment and prevention of the spread of this contagious disease, it remains a major public health threat with a high mortality rate. As several lethal SARS-CoV-2 variants continue to emerge, the development of several vaccines and medicines, each with certain advantages and disadvantages, is underway. Additionally, many modalities are at various stages of research and development or clinical trials. Here, we summarize emerging SARS-CoV-2 variants, including delta, omicron, and “stealth omicron,” as well as available oral drugs for COVID-19. We also discuss possible antigen candidates other than the receptor-binding domain protein for the development of a universal COVID-19 vaccine. The present review will serve as a helpful resource for future vaccine and drug development to combat COVID-19.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

1. Introduction ..................................................................................................... 3534
2. Structure and function of the coronavirus spike protein ............................................................... 3534
3. SARS-CoV-2 variants .................................................................................. 3536
4. Insights into a universal vaccine .................................................................................. 3537
4.1. S2 region of SARS-CoV-2 in public clonotype .......................................................... 3537
4.2. Hemagglutinin (HA) region of the influenza virus ...................................................... 3538
4.3. Current status of research into universal vaccines against other viruses .................... 3539
5. Antiviral chemicals for SARS-CoV-2 .................................................................................. 3540
5.1. Fusion inhibitors ........................................................................................ 3540
5.2. Protease inhibitors targeting cleavage sites ............................................................. 3541
5.3. Future prospects of antiviral medicine for COVID-19 treatment ..................... 3541
6. Summary and outlook .................................................................................. 3542
Declaration of Competing Interest .............................................................................. 3542
Acknowledgments ..................................................................................................... 3542
Funding .................................................................................................................. 3542

Abbreviations: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RBD, receptor binding domain; COVID-19, coronavirus disease 2019; S1-NTD, S1 N-terminal domain; S1-CTD, S1 C-terminal domain; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; ACE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane protease serine 2; HE, hemagglutinin-esterase; mAbs, monoclonal antibodies; HIV, human immunodeficiency virus; FDA, Food and Drug Administration.

Corresponding authors at: Department of Biotechnology, College of Life Sciences and Biotechnology, Seoul 02841, South Korea.
E-mail addresses: sulhee@korea.ac.kr (S. Kim), chahong@korea.ac.kr (K. Y. Hwang).

1 These authors contributed equally to this work.

https://doi.org/10.1016/j.csbj.2022.06.043
2001-0370/© 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

In January 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an “international public health emergency.” However, despite efficient transmission of information regarding COVID-19 during global quarantine, we failed to overcome the pandemic [1–6]. Given the lack of vaccines and treatments at the early stages of the pandemic, clinical testing stages and time taken for new vaccine development were significantly short. As a result, many people doubt the safety of the available vaccines. If infectious viruses, such as SARS-CoV-2, continue to emerge, pandemics will occur repeatedly, and humans will suffer enormous economic and political damage. At the start of the pandemic, when no specific vaccines or treatments were available, pre-existing cocktail treatments were administered to manage COVID-19. Although these treatments reduced mortality, increased recovery, and alleviated symptom severity, most approaches failed clinical trials. In this context, many scientists worldwide are involved in active research even today to find a preventive as well as curative vaccine/medicine for COVID-19. Currently, the urgent need for countermeasures against the pandemic has prompted rapid development of COVID-19 vaccines with diverse formulations. High efficacy and safety of the messenger RNA (mRNA) vaccines BNT162b2 (BioNTech-Pfizer) and mRNA-1273 (Moderna/NIAID) against COVID-19 have been demonstrated in clinical trials [1–3]. COVID-19 vaccines currently on the market produced by UK AstraZeneca, China’s CanSino Biologics, Russia’s Gamaleya Institute, and Belgium’s Janssen (Johnson & Johnson) also use this adenoviral-delivery strategy, although interest in this technology long predates the pandemic. However, in some cases, the level of antibodies decreases after infection or vaccination due to the continuous emergence of SARS-CoV-2 variants, and in a few cases, even previously immunized people are re-infected. In addition, variants including alpha, beta, delta, omicron, and the most recent “stealth omicron” have emerged in succession [4] (Fig. 1). Representative mutations include alpha mutations (B.1.1.7, September 2020), with seven mutated S proteins; beta mutations (B.1.351, October 2020), with nine mutated spikes; and omicron mutations (B.1.1.529, November 2021), with 30 mutated S proteins [5,6]. The recent Omicron variant substantially increased the number of confirmed cases in 2022. With many mutated S proteins, the ability of this variant to overcome immune responses, such as infection-blocking antibodies and T-cell responses, is high [5]. These trends underscore the need for a periodic immune-enhancing vaccine against COVID-19 [7–9]. Consequently, concerns regarding the increased infectiousness of the virus and controversies on the effectiveness of vaccines are growing [10,11]. In this context, interest in the development of oral antivirals, in addition to vaccines, is increasing. One of the most anticipated oral antivirals on the market to treat COVID-19 is molnupiravir, and fluvoxamine, are available [12]. Recently, a universal influenza vaccine was developed, which may take the threat of both seasonal and pandemic influenza “off the table” [13,14]. As defined by the National Institute of Allergy and Infectious Diseases (NIAID) in 2018, a “universal” vaccine implies at least 75% effectiveness in all age groups for a minimum of 1 year against all strains of influenza A [15]. Such knowledge and tools of successful universal vaccine research for influenza may be used in the development of a novel universal COVID-19 vaccine. Here, we discuss possible antigen candidates other than the receptor-binding domain (RBD) protein for universal COVID-19 vaccine development. The present review will serve as a critical reference for future vaccine and drug development against COVID-19.

2. Structure and function of the coronavirus spike protein

SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus. The 5’-two-third of the genome encodes polyproteins (pp1a and pp1ab), which are cleaved by 3C-like and papain-like proteases into 16 nonstructural proteins, including an RNA-dependent RNA polymerase [16]. The 3’-end of the genome encodes four essential structural proteins, namely spike (S), envelope (E), matrix/membrane (M), and nucleocapsid (N), along with a set of accessory proteins (Fig. 2A). Most vaccine candidates against SARS-CoV-2 aim to block infection by inducing neutralizing antibodies against the S protein, thereby preventing uptake through the human angiotensin-converting enzyme 2 (ACE2) receptor [17–19]. S protein is a structural glycoprotein expressed on the SARS-CoV-2 surface, and it is a critical determinant of viral host tissue tropism (Fig. 2B). It mediates virus entry into the target cells upon ACE2 receptor binding [16,20] and is thus an important therapeutic target [21,22]. Moreover, spike antigenicity has been highlighted through the observation of spike-specific CD4+ and CD8+ T cells in blood samples of recovered COVID-19 patients [23]. Consequently, the S protein of SARS-CoV-2 is a major target of prophylactic vaccination strategies [17–19]. Specifically, the S protein is cleaved into two subunits, namely S1 and S2, by extracellular proteases, including furin, host surface-associated membrane protease serine 2 (TMPRSS2), and endocytic cathepsin L [19,24–26] (Fig. 2B). Two cleavage sites at the S1 and S2 boundaries (S1/S2) and one in the S2 domain (S2’) play essential roles in virus entry into the host target cells [19,24–26]. S1 binds ACE2 through its RBD, and S2 is further cleaved and activated by TMPRSS2 and/or cathepsin L [19,24,26]. The S protein exists in two structurally distinct conformations: pre-fusion and post-fusion states (Fig. 3). In its pre-fusion state, it is a “closed” trimmer, with RBDs buried in the inner S1 head trimer at the interface between each protomer [27]. Each spike protomer harbors three segments: a large ectodomain (ED), a transmembrane anchor (TM), and a short intracellular tail (IC) [28]. ED comprises three critical elements: S1, RBD, and S2 (Fig. 2B). S1 consists of two subdomains, including an N-terminal domain (S1-NTD) and a C-terminal (S1-CTD) domain. RBD is located in S1-CTD and buried in the inner S1 head trimer. S2 constitutes a fusion peptide (FP), two heptad repeats (HR1 and HR2), a TM domain, and a cytoplasmic fusion (CT) domain, which are responsible for virus fusion and entry [28]. FP is a short part with 15–20 conserved amino acids in the viral family, mainly composed of hydrophobic residues, such as glycine or alanine. When the S
protein assumes its pre-hairpin conformation, it is immobilized on the target membrane, and FP is important for mediating membrane fusion through disrupting and ligating the lipid bilayer of the host cellular membrane [29]. While the S protein is an important target protein for specific drug development, RBD is part of a highly mutation-prone region and is not an ideal target site for the development of broad-spectrum antivirals [30]. In contrast, the HR region of S2 plays an essential role in SARS-CoV-2 infection and is preserved across SARS-CoV-2 mutants [31]. Peptides derived from the HR2 region of fusion protein of enveloped viruses competitively bind viral HR1, thereby effectively inhibiting viral infection [32,33]. Hemagglutinin-esterase (HE) is a family of viral glycoproteins that mediate reversible adhesion to O-acetylated sialic acids [34]. However, HE as a candidate therapeutic agent target-
ing SARS-CoV-2 is not appropriate because the SARS-CoV-2 genome lacks HE. Therefore, HR1 may be important for the study of fusion inhibitors to treat COVID-19.

3. SARS-CoV-2 variants

Several SARS-CoV-2 variants, including alpha, beta, delta, omicron, and the recent “stealth omicron” have emerged in succession [4]. Representative mutations include alpha mutations (B.1.1.7, September 2020), corresponding to seven S proteins mutations; beta mutations (B.1.351, October 2020), corresponding to nine spike mutations, and omicron mutations (B.1.1529, November 2021), corresponding to 30 S protein mutations [5,6] (Figs. 1, 4). Recently, the omicron variant has caused many confirmed cases till date. Due to many mutations, the ability of the variant to avoid immune responses, such as infection-blocking antibodies and T-cell responses, is high [5]. According to initial data, the delta variant was almost exclusively dominant until the end of November 2021, and the WHO designated the newly classified variant of concern as Omicron in only 2 days [35]. According to initial data, the delta variant was almost exclusively dominant until the end of November 2021, and the WHO designated the newly classified variant of concern as Omicron in only 2 days [35]. The parent omicron variant, which was designated BA.1 or B.1.1.529, was, until recently, the most transmissible known variant of the virus. More recently, one of its sub-lineages, designated BA.2, spread rapidly. BA.2 carries approximately 20 mutations that set it apart from the parent BA.1; however, it lacks the mutation that distinguishes omicrons from other variants in genetic PCR tests. Therefore, BA.2 has been named “stealth omicron.” This variant carries over 50 mutations in its genome, of which 30 are responsible for binding to the human ACE2 receptor for promoting infection and encoding the S protein of SARS-CoV-2 (Figs. 4, 5). As of February 2022, omicrons were the dominant variants worldwide. Omicron variants are also divided into BA.1, BA.2, BA.3, BA.4, BA5 and descendant lines. This also includes BA.1/BA.2 circulating recombinant forms such as XE [35]. Among these, BA.1 was once the most prevalent strain. However, BA.2 is gradually replacing BA.1 in some countries such as Denmark, Nepal, and the Philippines. BA.3 has a very limited transmissibility and shows very few cases of infection, at most a few hundred cases [36]. Therefore, we considered it prudent to summarize the variants for SARS-CoV-2 in detail.

Several coronaviruses, including SARS-CoV-2 and SARS-CoV-1, belong to the β-coronavirus group, one of the four groups (α-, β-, γ-, and ß-) of the Orthocoronavirinae subfamily of the Coronaviridae family [37]. Many members of the β-coronavirus lineage B (termed sarbecoviruses), including SARS-CoV; SARS-CoV-2 variants; and civet-, bat-, and pangolin-derived sarbecoviruses can exploit human ACE2 to enter host cells [38,39]. SARS-CoV-2 variants and pangolin-derived sarbecoviruses show a higher affinity to human ACE2 than SARS-CoV and civet- or bat-derived sarbecoviruses, which may be explained by the affinity-enhancing mutations present in the former [38,40]. Analysis of conserved protein sequences around the receptor-binding sites of 25 known sarbecovirus members relying on human ACE2 for cellular entry revealed that 11 of the 21 residues of the virus that interact with the receptor are highly conserved [41]. The two closely related viruses SARS-CoV-2 and SARS-CoV-1 share 75% similarity at the amino acid level and both rely upon human ACE2 release for viral influx [42]. There are 56 individual amino acid changes between the RBDs of SARS-CoV-2 and SARS-CoV-1 [43]. For instance, SARS-CoV-2 carries a D614G mutation located at the C-terminus of the S1 domain, near the furin cleavage site [44] (Figs. 1, 2). However, there is currently no scientific consensus on positive selection for the G614 variant, which is associated with higher infectivity and transmissibility in humans [45]. Importantly, in a hamster model, antibodies against SARS-CoV-2 D614G potently neutralized infection with its G614 counterpart [46], suggesting that the D614G mutation would not reduce the protective ability of vaccines in clinical trials. Typically, however, as opposed to single-
amino acid changes, most combinations of several mutations destroy many key epitopes, which may lead to the loss of serum activity (Figs. 3, 4, 5). Normally, the neutralization effect of spike-specific monoclonal antibodies (mAbs) on the mutant SARS-CoV-2 spike is greatly reduced. In contrast, polyclonal antibodies remain active against most mutant spike-like types, albeit being less effective against a few mutants [46]. These viruses use the same spike region of ACE2 RBD, enabling SARS-CoV-2 sera to isolate cross-neutralizing mAbs [47]. Vaccines and treatments targeting the virus must be continuously updated owing to the occurrence of several virus mutations designed to adapt to the environment [46,48–51]. Therefore, the effectiveness of currently available vaccines targeting SARS-CoV-2-induced antibodies against several variants must be examined [46].

Changes in individual amino acids make it difficult for mAbs to effectively neutralize viral mutations. mAbs are less likely to produce an effective neutralizing effect on viral mutations, because the existing antibody neutralization function decreases every time an amino acid mutation occurs in the binding part of the antibody. Interestingly, regarding new vaccine development, some antibodies, such as S2-targeting mAbs, act as common antibodies against both SARS-CoV-2 and SARS-CoV-1 [52]. If the common epitope of S2 is an antibody RBD target that produces fewer mutations and is likely to exist in all SARS-CoV-2 mutants, a universal vaccine for multiple variants can be developed by targeting the new epitope of SARS-CoV-2.

4. Insights into a universal vaccine

4.1. S2 region of SARS-CoV-2 in public clonotype

Generally, viruses use various mechanisms, such as molecular mimicry and 2’-O methylation to induce immune escape process, which acts against the host immune system [53,54]. Since the emergence of SARS-CoV-2, its RBD has evolved through several mutations from alpha to omicron. Many studies have identified antibodies against the S1 and S2 regions, most of which are neutralizing antibodies targeting the RBD of S1 regions to repress ACE2 receptor binding [55–59]. However, vaccines containing S1 are less effective against several variants because many amino acids in S1-RBD are mutated. For instance, the Pfizer-
BioNTech (or BNT162b2) vaccine showed 95% efficacy against wild-type SARS-CoV-2, 87% against B.1.1.7 (alpha) variants, and 72.1 against B.1.351 (beta) variants [60]. Therefore, universal vaccine development has gained much attention to ensure efficacy against persistent viral mutations (Fig. 4).

Interestingly, 37 common antibodies (public clonotypes) were recently detected in people with COVID-19 or vaccinated individuals, of which 27 were shared among individuals who had recovered from infection and those who had been vaccinated [41]. Clonotypes provide important information regarding vaccine responses in a large human population. Shared public clonotypes form a significant proportion of human B-cell responses induced by the S trimer and produce neutralizing antibodies against RBD in the S2 of SARS-CoV-2 [41,61]. Among these, two single antibodies recognize the conserved regions of S proteins that are not mutated in SARS-CoV-2 and SARS-CoV-1 [62]. Among the public clonotypes, antibodies targeting S2 include immunoglobulin heavy variable (IGHV)1-58, IGHV3-53, IGHV3-66, IGHV3-30, and IGHV3-30-3 [56]. Majority of the public clonotypes are IgGs, while some are subsets of IgA. Of the 37 public clonotypes identified, 16 can bind RBD, and 11 of these 16 are neutralizing spikes. All neutralizing public clonotypes recognize RBD. Meanwhile, the remaining 21 of the 37 public clonotypes can bind antigenic sites (including S2 domains) other than RBD. Overall, these results suggest that many public clonotypes have been detected between vaccinated and infected individuals.

4.2. Hemagglutinin (HA) region of the influenza virus

The influenza virus has been in vogue worldwide since 1918. Currently available seasonal influenza vaccines provide...
narrow-spectrum and short-term yet effective protection against these viruses. The key target in the development of a universal vaccine is the conserved region. Generally, the human immune system recognizes HA, neuraminidase (NA), nucleoprotein (NP), and matrix proteins 1 (M1) and 2 (M2). Among these, conserved regions, such as the stem region of HA and M2, are targeted for universal vaccine development. In the case of influenza virus, attempts have been made to remove the HA1 subunit of HA using chemical or genetic methods for the development of a universal vaccine [68,69]. However, chemical removal of HA1 causes several problems, including protein damage during chemical treatment and loss of part of the HA1 stem site, which impedes the action of antibodies on HA2 [68]. In addition, genetic modification to remove HA head was unsuccessful because it did not produce a reliable full-stem protein. Although headless HA produced by insect cells has been successfully used against H1N1, H5N1, and H6N1 strains [69], the structural instability of the stem region remains unresolved [70,71]. Thus, headless HA may be an important candidate for the development of universal vaccines.

4.3. Current status of research into universal vaccines against other viruses

Chimeric vaccines use chimeric antigens, which are a “mix” of various regions of antigens. Although chimeric vaccines against many viruses, such as dengue fever [72], yellow fever [73], and influenza [74] viruses, have been studied extensively, none has passed all essential clinical procedures. Sarbecovirus, including SARS-CoV-2, SARS-CoV, and many other viruses with zoonotic potential, harbor S proteins, which comprise NTD, RBD, and S2. Since antibodies can be derived from all regions of S protein in addition to RBD [75], this region has been exploited to induce a wide range of antibodies through chimeric vaccines and positive results have been reported [71]. In the case of coronaviruses, S protein is the target of “mixed antigens.” Chimeric S proteins are known to elicit a broad-range cellular immune response, offering an opportunity to develop a universal vaccine. For instance, four types of chimeric S proteins have been designed (Fig. 6). In a previous study on primed and boosted aged mice, all chimeric S

Fig. 6. Sarbecovirus chimeric spike designs. (A) Simple structure model of coronavirus S glycoprotein. Blue area indicates the whole S2 region. RBD, receptor binding domain; NTD, N-terminal domain. (B) Schema of designed chimeric spike proteins. Each part of chimera 1 comprises three different strains and the others (chimeras 2–4) comprise of two different strains. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
proteins showed high cross-activity against SARS-CoV, SARS-CoV-2, HKU-1, and RsSHC014 strains. HKU-1 is a coronavirus discovered in Hong Kong in 2004 [76]. RsSHC014 is a bat-derived SARS-like coronavirus discovered in China in 2013 [77]. Parvathaneni et al. [78] conducted a similar study.

Mosaic vaccines are similar to chimeric vaccines in that they induce a wide range of immune responses against multiple strains. In a previous study, whole S proteins from selected strains were conjugated in a particle using the SpyTag/SpyCatcher technique, similar to a mosaic (Fig. 7) [79]. Mosaic vaccines have been actively studied, particularly in the context of human immunodeficiency virus (HIV) [80]. In 2009, the effectiveness of RV144, a vaccine for HIV type 1, was demonstrated, which prompted additional studies on mosaic vaccines. RV144 follows the principle of heterologous prime-boost by combining ALVAC-HIV and AIDSVAX B/E vaccines [80], and it could successfully reduce HIV infection by up to 31.2% [81]. In a previous nanoparticle-based study [82], four mosaic vaccines for COVID-19 were developed by combining different RBDs. Of these, two were derived by combining four different RBDs from β-coronavirus strains; one was derived by combining eight different RBDs; and the remaining comprised SARS-CoV-2 RBD alone, acting as the wildcard SARS-CoV-2 antigen [83]. Each preliminary vaccine was administered to mice, and their immune response was analyzed. Compared with the control homotypic SARS-CoV-2 vaccine, mosaic vaccines induced a broader immune response in mice [82].

FP is a region of the S protein that aids the evasion of viruses into the host cell. FP bears highly conserved amino acid residues within a virus family [83]. This feature renders FP a suitable target for the development of universal vaccines. Trials of FP vaccines against porcine epidemic diarrhea virus (PEDV)—which belongs to the subgenus of β-coronaviruses—and SARS-CoV-2 have been conducted [84]. Despite the use of an innovative vaccine platform, the results highlighted the feasibility of a universal FP vaccine.

Finally, T-cell vaccines, which are peptide vaccines, can be a solution to manage SARS-CoV-2 variants. These vaccines can be effective in patients with B-cell deficiency (immune deficiency) who lack the ability to produce antibodies. Nathan et al. [85] used a structure-based network and HLA class I stability peptide analysis to successfully identify highly conserved regions of CD8+ T-cell epitopes. Other vaccines are considered to provide broad immunity against variants and other sarbecoviruses.

5. Antiviral chemicals for SARS-CoV-2

Interest in the development of oral antiviral drugs is growing given the need for periodic immune-boosting vaccines against SARS-CoV-2, concerns regarding increase in the infectivity of the virus, and doubts on the effectiveness of the vaccine. One of the most anticipated oral antivirals on the market to treat SARS-CoV-2 is Paxlovid (Pfizer), which is an oral medication that can reduce the severity of COVID infection, when administered promptly. In addition, several novel oral antivirals or candidates, including nirmatrelvir/ritonavir (Paxlovid), molnupiravir, and fluvoxamine, were available as of February 2022 [13]. Nirmatrelvir is an orally bioavailable protease inhibitor that acts against M-PRO—a viral protease playing an essential role in viral replication by cleaving two viral polyproteins [86]. Nirmatrelvir exhibits antiviral activity against all coronaviruses known to infect humans [87]. Nirmatrelvir is packaged with ritonavir (as Paxlovid)—a strong cytochrome P450 (CYP) 3A4 inhibitor and a pharmacokinetic boosting agent of HIV protease inhibitors. Ritonavir co-administration is essential to increase nirmatrelvir concentration in the target therapeutic range. Molnupiravir is a small-molecule ribonucleoside prodrug of N-hydroxycytidine, which acts against SARS-CoV-2 and other RNA viruses and serves as a potent barrier to virus resistance development [97]. Fluvoxamine is a selective serotonin reuptake inhibitor approved by the Food and Drug Administration (FDA) for the treatment of obsessive–compulsive disorder and other conditions, including depression. However, fluvoxamine is not FDA-approved for the treatment of any infectious disease. Trials to confirm the anti-inflammatory effects of fluvoxamine observed in non-clinical studies in humans and its clinical relevance in the COVID-19 setting are ongoing. However, the COVID-19 Treatment Guidelines Panel has insufficient evidence to support or reject the use of fluvoxamine as COVID-19 treatment. Here, we summarize the target groups of related oral chemicals or candidates for COVID-19.

Table 2

| Peptide | Sequence |
|---------|----------|
| EK1     | SLDQINVTFLDEYMMKKLEAEKIKLEESYIDLKEL (cholesterol) |
| EK1C4   | SLDQINVTFLDEYMMKKLEAEKIKLEESYIDLKELGSGSG-PEG4 (cholesterol) |
| IPB02   | ISGINAVNIIQEIDRLNEVAKNLNESLIDQELK (cholesterol) |

5.1. Fusion inhibitors

In SARS-CoV, the S2 subunit is an essential component of the fusion process during the entry of the virus into the host cell. The HR1 and HR2 domains interact to form helical bundles in the S2 subunit. This helical bundle binds the cell membrane and allows fusion [88]. Based on their high similarity, the sequences of HR2 domains of SARS-CoV-2 and SARS-CoV-1 are conserved. The SARS-CoV-2 HR2 protein (residues 1168–1203) inhibits virus entry into host cells or fusion. Specifically, the IC50 of SARS-CoV-2 HR2 protein against SARS-CoV-2 pseudovirus was 0.98 mM [33,89]. OC43-HR2P is a modified peptide derived from the HR2 domain of HcoV-OC43, a type of β-coronavirus 1 that infects humans and cattle [90]. Compared with SARS-CoV, MERS-CoV, and SARS-CoV-2, HcoV-OC43 manifests milder symptoms [91]. EK1 is a fusion inhibitor targeting the HR1 domain of HcoV S protein in pan-coronaviruses (Table 2). EK1 is more soluble in phosphate-buffered saline and water than the existing OC43-HR2P [32]. A peptide-based inhibitor, such as EK1, can inhibit the fusion of SARS-CoV-2 with the host. Based on crystal structure, the HR2 and HR1 domains of SARS-CoV-2 interact to form a helical bundle, suggesting that amino acid mutations in HR1 can improve its interaction with HR2 [92]. EK1C4, a lipopeptide originating from EK1, suppressed the fusion of SARS-CoV-2 with host cells. EK1C4 is formed by adding polyethylene glycol, cholesterol, and a fusion linker to the amino acid sequence of EK1 (Table 2). EK1C4 inhibited the entry of SARS-CoV-2 pseudovirus into the host cells, with an IC50 of 15.8 nm, which was approximately 149 times higher than that of EK1 [93]. IPB02, a lipopeptide fusion inhibitor based on a different sequence, inhibited the fusion to SARS-CoV-2 pseudovirus to prevent infection [94] (Table 2).

EK1 is a peptide drug, while EK1C4 and IPB02 are lipopeptide drugs. Lipidation is useful because it can enhance in vivo activity. EK1C4 covalently binds cholesterol at the C-terminus of EK1. The spacer based on polyethylene glycol and GSG is a glycerine/serine sequence. Since the efficacy of the drug could be increased by extending the GSG linker to GSGSG for a longer period, increasing the length of the linker in lipopeptide is the key. IPB02 is an HR2-derived fusion inhibitor, with cholesterol covalently bound to its terminal end.
5.2. Protease inhibitors targeting cleavage sites

Entry into the host cell requires cleavage between the S2 subunit and S1 and S2 of SARS-CoV-2. Degradation by TMPRSS2 and cathepsin L and B plays an essential role in SARS-CoV-2 entry into the host cell. TMPRSS2 is a serine protease that promotes virus entry and activation by cleaving S proteins. Membrane fusion cannot proceed without proteolysis; thus, TMPRSS2 is important for SARS-CoV2 fusion with the host cells. Camostat mesilate is a potential serine protease inhibitor that targets TMPRSS2 (Fig. 8). A study on the cellular entry mechanism of SARS-CoV-2 demonstrated that camostat mesilate inhibited virus entry into host cells [93]. E-64d, a cathepsin L inhibitor, blocked SARS-CoV-2 infection. Future trials involving patients with COVID-19 may help identify the efficacy of E-64d therapy [95] (Fig. 8). In addition to peptide fusion inhibitors, nelfinavir mesylate (Viracept), an anti-HIV protease inhibitor, inhibits both S- and S-mediated cell–cell fusion of SARS-CoV-2. Viracept was the first reported small-molecule fusion inhibitor, other than peptide fusion inhibitors (Fig. 8). In addition, nelfinavir inhibits the function of TMPRSS2, which is involved in S protein cleavage [96]. This finding has allowed for the clinical application of anti-SARS-CoV-2 therapeutics, particularly at the early stages of infection. Among phospholipids, furin with phosphatidylcholine (PC) hydrolyzes peptide substrates at basic residues [97]. The S protein of SARS-CoV-2 has furin cleavage sites at the S1/S2 boundary, and they can enhance replication efficiency of the virus upon entry into the host cell [98]. Cleavage sites similar to the furin cleavage sites of SARS-CoV-2 can affect the viral life cycle and pathogenicity. Accordingly, inhibitors targeting multiple cleavage sites, including furin inhibitors, can be used as drug therapies for COVID-19.

5.3. Future prospects of antiviral medicine for COVID-19 treatment

As an important component for interaction with the host, the S protein of SARS-CoV-2 is a significant target for vaccine or neutralizing antibody development. As such, if the mechanism of interaction with the host is elucidated, the enzyme involved is inhibited,
and the ion channel is blocked, a potent antiviral effect can be produced. Of note, EK1C4 targeting the highly conserved HR1 domain of the S2 subunit was expected to exhibit therapeutic potential against SARS-CoV-2 (Table 2). In addition, a combination of different antiviral agents has been proposed as a solution to combat the disease. Similarly, a recent study has demonstrated the sensitivity of the omicron variant of SARS-CoV-2 to the combination of molnupiravir and nirmatrelvir [99] (Fig. 7). In particular, nirmatrelvir is an antiviral medicine developed by Pfizer and an oral protease inhibitor. In December 2021, the potent inhibitory effect of Paxlovid, prepared by combining nirmatrelvir and ritonavir, against SARS-CoV-2 was proven, and it was approved for emergency use by the FDA [100]. Molnupiravir is an oral antiviral drug developed for the treatment of influenza; it inhibits infection by inducing errors in viral RNA replication [101]. Molnupiravir is currently approved in the UK for the treatment of COVID-19 [102] (Fig. 7). Based on their chemical functions, both molnupiravir and nirmatrelvir exhibit antiviral properties, and the combination of these two produces a synergistic effect, which may be a potential solution to manage emerging SARS-CoV-2 variants. Novel effective antiviral drugs can be developed through the combination of existing drugs for the treatment of COVID-19. Finally, if issues related to the accessibility and cost effectiveness of oral antiviral agents are resolved, they may prove revolutionary in the management of emerging variants of SARS-CoV-2.

6. Summary and outlook

For the prevention and treatment of COVID-19, rapid development of neutralizing antibodies against SARS-CoV-2 in convalescent patients represents an important scientific challenge at present. Several vaccines have been developed and distributed at an unprecedented rate to combat the COVID-19 pandemic. However, the persistent emergence of new SARS-CoV-2 variants has impeded treatment using neutralizing antibodies and reduced the effectiveness of vaccines. In this context, development and implementation of novel vaccine designs and technologies are anticipated. Periodic screening for the efficacy of neutralizing antibodies and vaccines against new emerging pathogenic variants is warranted. In this review, we have summarized oral medicines and emerging SARS-CoV-2 variants, such as delta and omicron. In addition, we have briefly discussed the possible antigen candidates (mainly the S2 region) other than RBD for the development of a universal COVID-19 vaccine. This review will be helpful for future vaccine and drug development against COVID-19.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We acknowledge the program for undergraduate student at Division of Biotechnology in Korea University.

Funding

This work was supported by the National Research Foundation of Korea [grant numbers 2020R1A2C2005670, 2018M3A9F3055925, and 2022R1I1A1A01068223]. S.K. and K.Y.H received Korea University grants.

Author contributions

K.Y.H. and S.K. wrote manuscripts; S.K. performed mutants analysis and prepared the figures; E.Y. and D.K. analyzed the COVID-19 variants and vaccine data. H.J. Y.K. and Y.J. analyzed the COVID-19 oral drugs.

References

[1] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 15;384:403–16. https://doi.org/10.1056/NEJMoa2031899
[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 15;383:2603–15. https://doi.org/10.1056/NEJMoa2034272
[3] Walsh EE, French RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 15;383:2439–50. https://doi.org/10.1056/NEJMoa2077906.
[4] Chavda VP, Apostolopoulos V. Omicron variant (B.1.1.529) of SARS-CoV-2: threats for the elderly. Maturitas 2022;158:78–81. https://doi.org/10.1016/j.maturitas.2022.03.011
[5] El-Shabasy RM, Nayel MA, Taher MM, Abdelmonem R, Shoueir KR, Kenawy ER. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. J Macromol Sci: B 2022;204:161–8. https://doi.org/10.1016/j.jmb.2022.01.118
[6] Konings F, Perkins MD, Kuhn JH, Pallen MJ, Alm EJ, Archer BN, et al. SARS-CoV-2 variants of interest and concern naming scheme conducible for global discourse. Nat Microbiol 2021;6:821–3. https://doi.org/10.1038/s41564-021-00932-y
[7] Falsey AR, French RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-CoV-2 neutralization with BNT162b2 virus Dose 3. N Engl J Med 2021;385:1627–9. https://doi.org/10.1056/NEJMoa2113468
[8] Levin AT, Hanage WP, Owuosa-Boatey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Public Health 2020:35:1721–38. https://doi.org/10.1097/524-0000000000000618
[9] Khejher J, Horton LB, Birnink NJ, Laurent LC, SEARCH Alliance, Pride D, et al. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med 2021;385:1330–2. https://doi.org/10.1056/NEJMoa2112881.
[10] Ingraham NE, Ingbah DH. The omicron variant of SARS-CoV-2: understanding the known and living with unknowns. Clin Transl Med 2021;11:e685.
[11] UK Health Security Agency. Accessed 2022. 02.13. SARS-CoV-2 variants of concern and variants under investigation in England. https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-of-concern-20201201
[12] Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19-a meta-analysis. Ann Med 2022;54:516–23. https://doi.org/10.1080/07853890.2022.1949846.
[13] National Institute of Allergy and Infectious Diseases. Universal influenza vaccine research [accessed 2022.02.13]. https://www.niaid.nih.gov/diseases-conditions/universal-influenza-vaccine-research; updated 2019.
[14] Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med 2021;27:106–14. https://doi.org/10.1038/s41591-021-01118-7.
[15] Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health 2022;15:228–40. https://doi.org/10.1016/j.jiph.2022.03.014.
[16] Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020;6:315–31. https://doi.org/10.1021/acscentsci.0c00277
[17] Fehr AR, Perlman S. Coronavirus: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1–23. https://doi.org/10.1007/978-1-4939-2438-7_1.
[18] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3. https://doi.org/10.1038/s41586-020-0212-7.
[19] Hoffmann M, Klein-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:294–307.e11. https://doi.org/10.1016/j.cell.2020.02.052.
[20] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res 2020;7:11. https://doi.org/10.1186/s40779-020-00240-0.
[21] Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respir Res 2018;19:130–7. https://doi.org/10.1186/s12931-018
Zheng Z, Monteil VM, Maurer-Stroh S, Yew CW, Leong C, Mohd-Ismail NK, E. Yoon, D. Kim, H. Jeon et al. Computational and Structural Biotechnology Journal 20 (2022) 3533–3544

Wrobel AG, Benton DJ, Xu P, Calder LJ, Borg A, Roustan C, et al. Structure and

Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep 2021;35(109292).

Oude Munnik BBO, Wijn P, Nieuwenhuis BF, Sikkema RS, Haagmans B, Fouchier RAM, et al. The neutral phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. Nat Med 2021;27:1518–24. https://doi.org/10.1038/s41591-021-01472-w

Wilkins SA, Sotero C, Amaduzzi M, Ianzugandh A, Fonsco A, Ghadihuri J et al (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. Preprint at https://doi.org/10.1101/2020.02.05.995608

Wellsler MRA, Han AX, Reusken CEBM, Eggun D. Possible host-adapteration of SARS-CoV-2 due to improved ACE2 receptor binding in mink. Virus Evol 2021;7:vvea094. https://doi.org/10.1093/viruses/vvea094

Zacks S, Mosieni V, Guglielmino P,中秋 VC, Hod Mosh-Iskak NL, et al. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 coronavirus with the newly emerged SARS-CoV-2. Euro Surveill 2020;25. 10.2807/1560-7917.ES.2020.25.28.3270671.

Albarnaz JD, Ren H, Torres AA, Shmeleva EV, Melo CA, Bannister AJ, et al. Molecular mimicry of NF-κB by vaccination virus protein enables inhibition of antiviral responses. Nat Med 2022;27:154–68. https://doi.org/10.1038/s41591-021-01404-6

Dafnis S, Sretzer R, Schiewer J, Li Y, You S, Ferrett J, et al. 2-O-methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010;468:452–6. https://doi.org/10.1038/nature09489.

Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang G, et al. Potent neutralizing antibodies against emerging SARS-CoV-2 spike. Nature 2020;584:450–6. https://doi.org/10.1038/s41586-020-2571-7

Robbiansi DF, Geaeher C, Muescks F, Lorenzi JCC, Wang Z, Chi A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Proc Natl Acad Sci USA 2020;117:23847–56. https://doi.org/10.1073/pnas.2015858117

Seydoux E, Honhad J, Macayam AJ, Parks RK, Hurhurt NK, Jennewein MF et al (2020) Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. https://doi.org/10.1101/2020.05.12.209128.

Wils IV, Bhattacharjee C, Perrett AS, Maurer DP, Hadwaster D, Sakharuk M, et al. Broad neutralization of SARS-CoV-related viruses by monoclonal antibodies. Science 2020;369:731–6. https://doi.org/10.1126.science.aba763.

Zost SJ, Ghilchuk P, Chen BE, Case JB, Redy JX, Trivette A, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med 2020;26:1442–7. https://doi.org/10.1038/s41591-020-0996-z

Han X, Ye Q, The variants of SARS-CoV-2 and the challenges of vaccines. J Med Virol 2022;94:1366–72. https://doi.org/10.1002/jmv.27513.

Soto C, Bombardi RG, Kochevnikov M, Sinkovits RS, Chen EC, Branchioz A, et al. High frequency of shared clonotypes in human T cell receptor repertoire. Cell Rep 2020;32:100906. https://doi.org/10.1016/j.celrep.2020.107882.

Hisham Y, Ashhab Y, Hwang SH, Kim DE. Identification of highly conserved epitopes on SARS-CoV-2 spike to design recombinant fusion inhibitors. Sci Rep 2020;10:13160. https://doi.org/10.1038/s41598-020-69753-3.

Kirkpatrick E, Qiu X, Wilson PC, Bahl J, Krammer F. The influenza virus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Transl Med 2021;13:eabi4506. https://doi.org/10.1126/scitranslmed.abi4506.

Brame RS, Rapp DP, Berret AS, Maurer DP, Hadwaster D, Sakharuk M, et al. Broad neutralization of SARS-CoV-related viruses by monoclonal antibodies. Science 2020;369:731–6. https://doi.org/10.1126.science.aba763.

Zost SJ, Ghilchuk P, Chen BE, Case JB, Redy JX, Trivette A, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med 2020;26:1442–7. https://doi.org/10.1038/s41591-020-0996-z

Wils IV, Bhattacharjee C, Perrett AS, Maurer DP, Hadwaster D, Sakharuk M, et al. Broad neutralization of SARS-CoV-related viruses by monoclonal antibodies. Science 2020;369:731–6. https://doi.org/10.1126.science.aba763.

Van den Burg D, De Jongh H, Bolhj B, Culic C. Salic acid O-acetylation: from biosynthesis to roles in health and disease. J Biol Chem 2021;297:110996–9. https://doi.org/10.1074/jbc.R120026.201.

Yuan M, Liu H, Wu NC, Lee CD, Zhu X, Zhao F, et al. Structural basis of a shared receptor-binding domain complexed with receptor. Science 2020;369:1119–23. https://doi.org/10.1126/science.abc7263.

Menachedy V, Yount DL, Debbink K, Agnihotham S, Gralinus LE, Plante JA, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 2021;17:1508–13. https://doi.org/10.1038/s41591-021-01472-w

Martinez RD, Schaefer A, Leist SR, De la Cruz G, West A, Atrachina-Vasserman EN, et al. Chimeric spike mRNA vaccines protect against Sarscovivirus challenge in mice. Science 2021;373:991–8. https://doi.org/10.1126/science.abc7263.

Kirkpatrick E, Qiu X, Wilson PC, Bahl J, Krammer F. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci Rep 2018;8:10432. https://doi.org/10.1038/s41598-018-28700-1

Grains MN, Schulman JL, Young JP, Palese P. Preparation of influenza virus subviral particles lacking HA2. A novel tool for vaccine development: H5N1 vaccine candidates. J Virol 2018;92:4095–4100. https://doi.org/10.1128/JVI.03665-17.

Wollhöld T, Nachbager R, Margine I, Tan GS, Hirsh A, Krammer F. Vaccination with subviral particles lacks of the hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983;126:106–16. https://doi.org/10.1016/0042-6822(83)90405-8.

Abuabara H, Sivapullaiah S, Welford MV, Zhu X, Hoffman BM, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015;349:1301–6. https://doi.org/10.1126/science.1262573.

Dansereau HM, Boyington JC, McTaminney WP, Wei CJ, Kanekiyo M, Kong WP, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015;21:1605–7. https://doi.org/10.1038/nm.3927.

Murrell S, Wu SC, Butler M. Review of Dengue virus and the development of a vaccine. Biotechnol Adv 2011;29:239–47. https://doi.org/10.1016/j.biotechadv.2010.11.008.
[73] Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 2016;34:1643–7. https://doi.org/10.1016/j.vaccine.2016.02.056.

[74] Krammer F, Pica N, Hai R, Margine I, Palese P. Chimeric hemagglutinin influenza virus constructs elicit broadly protective stalk-specific antibodies. J Virol 2013;87:6542–50. https://doi.org/10.1128/JVI.00641-13.

[75] Voss WN, Hou YJ, Johnson NV, Delidakis G, Kim JE, Javanmardi K, et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science 2021;372:1108–12. https://doi.org/10.1126/science.abe2568.

[76] Woe PCY, Lau SKP, Chu CM, Chan KH, Tsoi HW, Huang Y, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005;79:884–95. https://doi.org/10.1128/JVI.79.2.884-895.2005.

[77] Ge XY, Li JJ, Yang XL, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013;503:535–8. https://doi.org/10.1038/nature12711.

[78] Parvathaneni K, Torres-Rodriguez K, Meng W, Hwang WT, Frey N, Najj A, et al. SARS-CoV-2 spike-specific T-cell responses in patients with B-cell depletion who received chimeric antigen receptor T-cell treatments. JAMA Oncol 2022;8:164–7. https://doi.org/10.1001/jamaoncol.2021.6030.

[79] Keeble AH, Howarth M. Power to the protein: enhancing and combining activities using the Spy toolbox. Chem Soc Rev 2020;49:7281–91. https://doi.org/10.1039/D0CS01878C.

[80] Rekers-Ngarm S, Pitsutthituph P, Nitaayapan S, Kaewkungwal J, Chiu J, Pari S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209–20. https://doi.org/10.1056/NEJMoa0908492.

[81] Musarrat F, Chouljenko V, Dahal A, Nabi R, Chouljenko T, Jois SD, et al. The anti-HIV drug nefillinavir mesilate (Virapect) is a potent inhibitor of cell fusion caused by the SARS-CoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J Med Virol 2020;92:2087–95. https://doi.org/10.1002/jmv.25985.

[82] Tang T, Jaimes JA, Bidon MK, Straus MR, Daniel S, Whittaker GR. Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond Furin. ACS Infect Dis 2021;7:264–72. https://doi.org/10.1021/acsinfecdis.0c00701.

[83] Düzgünes N, Fernandez-Fuentes N, Konopka K. Inhibition of viral membrane fusion by peptides and approaches to peptide design. Pathogens 2021;10:1599. https://doi.org/10.3390/pathogens10121599.

[84] Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y, et al. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm Sin B 2021;22:11–38. https://doi.org/10.1016/j.apsb.2021.06.016.

[85] Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: a review of virus–host interactions. Diseases 2016;4. https://doi.org/10.3390/diseases4030026.

[86] Zhau Y, Yu D, Hu Y, Wu T, Cheng H, He Y. SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther 2021;6:294. https://doi.org/10.1038/s41392-021-00698-x.

[87] Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther 2021;6:134. https://doi.org/10.1038/s41392-021-00558-8.

[88] Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: a review of virus–host interactions. Diseases 2016;4. https://doi.org/10.3390/diseases4030026.

[89] Zhu Y, Yu D, Hu Y, Wu T, Cheng H, He Y. SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther 2021;6:294. https://doi.org/10.1038/s41392-021-00698-x.

[90] Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: a review of virus–host interactions. Diseases 2016;4. https://doi.org/10.3390/diseases4030026.

[91] Lü P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res 2022;32:322–4. https://doi.org/10.1038/s41422-022-01032-x.

[92] Robbins R, Zimmer C. Clears Pfizer’s Covid pill for high-risk Patients 12 and older. The New York Times. 12. F.D.A; 2021.

[93] Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plumper RK. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res 2020;218:16–28. https://doi.org/10.1016/j.trsl.2019.12.002.

[94] Delgado BM, Hawn TR, Davis CC, Niewold TB, Marchant DL, Brown MD, et al. Combination therapies for COVID-19: Leveraging (molnupiravir), approved by MHRA, https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra; 2021. Government of The United Kingdom.